Three insights:
1. Spiderwort is in the pre-clinical stage of developing a biomaterial that uses plant-derived cellulose to generate “scaffold architectures” for regenerative medicine.
2. The company’s biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration in pre-clinical trials.
3. Spiderwort seeks to raise a round of Seed funding, complete further pre-clinical testing and achieve regulatory approvals to move towards commercialization of the technology.
More articles on biologics:
Dr. Robert LaPrade on the biggest thing to hit sports medicine since the arthroscope
Ossio wins Frost & Sullivan award for bone regeneration technology — 4 insights
InGeneron raises $43M financing for regenerative cell shoulder program
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
